FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3135712462> ?p ?o ?g. }

• W3135712462 abstract "Abstract Background Solid tumor hypoxic conditions prevent the generation of reactive oxygen species (ROS) and the formation of DNA double-strand breaks (DSBs) induced by ionizing radiation, which ultimately contributes to radiotherapy (RT) resistance. Recently, there have been significant technical advances in nanomedicine to reduce hypoxia by facilitating in situ O 2 production, which in turn serves as a “radiosensitizer” to increase the sensitivity of tumor cells to ionizing radiation. However, off-target damage to the tumor-surrounding healthy tissue by high-energy radiation is often unavoidable, and tumor cells that are further away from the focal point of ionizing radiation may avoid damage. Therefore, there is an urgent need to develop an intelligent targeted nanoplatform to enable precise enhanced RT-induced DNA damage and combined therapy. Results Human epidermal growth factor receptor 2 (Her2)-specific dimeric affibody (Z Her2 ) mediated cisplatin-loaded mesoporous polydopamine/MnO 2 /polydopamine nanoparticles (Pt@mPDA/MnO 2 /PDA-Z Her2 NPs) for MRI and enhanced chemo-radiotherapy of Her2-positive ovarian tumors is reported. These NPs are biodegradable under a simulated tumor microenvironment, resulting in accelerated cisplatin release, as well as localized production of O 2 . Z Her2 , produced using the E. coli expression system, endowed NPs with Her2-dependent binding ability in Her2-positive SKOV-3 cells. An in vivo MRI revealed obvious T 1 contrast enhancement at the tumor site. Moreover, these NPs achieved efficient tumor homing and penetration via the efficient internalization and penetrability of Z Her2 . These NPs exhibited excellent inhibition of tumor growth with X-ray irradiation. An immunofluorescence assay showed that these NPs significantly reduced the expression of HIF-1α and improved ROS levels, resulting in radiosensitization. Conclusions The nanocarriers described in the present study integrated Her2 targeting, diagnosis and RT sensitization into a single platform, thus providing a novel approach for translational tumor theranostics. Graphic abstract" @default.
• W3135712462 created "2021-03-15" @default.
• W3135712462 creator A5016354966 @default.
• W3135712462 creator A5018972190 @default.
• W3135712462 creator A5032473290 @default.
• W3135712462 creator A5038714250 @default.
• W3135712462 creator A5045541975 @default.
• W3135712462 creator A5056451408 @default.
• W3135712462 creator A5063870450 @default.
• W3135712462 creator A5064415871 @default.
• W3135712462 creator A5077420983 @default.
• W3135712462 creator A5084846045 @default.
• W3135712462 date "2021-05-13" @default.
• W3135712462 modified "2023-10-14" @default.
• W3135712462 title "Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy" @default.
• W3135712462 cites W1891354937 @default.
• W3135712462 cites W1912124796 @default.
• W3135712462 cites W1975840738 @default.
• W3135712462 cites W2008883059 @default.
• W3135712462 cites W2025033391 @default.
• W3135712462 cites W2026576427 @default.
• W3135712462 cites W2031767134 @default.
• W3135712462 cites W2041759339 @default.
• W3135712462 cites W2042175907 @default.
• W3135712462 cites W2051845341 @default.
• W3135712462 cites W2077787026 @default.
• W3135712462 cites W2094288422 @default.
• W3135712462 cites W2103719918 @default.
• W3135712462 cites W2134450909 @default.
• W3135712462 cites W2135378138 @default.
• W3135712462 cites W2158155063 @default.
• W3135712462 cites W2267591082 @default.
• W3135712462 cites W2328301720 @default.
• W3135712462 cites W2335405043 @default.
• W3135712462 cites W2413193118 @default.
• W3135712462 cites W2512217706 @default.
• W3135712462 cites W2570510763 @default.
• W3135712462 cites W2593483585 @default.
• W3135712462 cites W2614353472 @default.
• W3135712462 cites W26155307 @default.
• W3135712462 cites W2621697894 @default.
• W3135712462 cites W2621849512 @default.
• W3135712462 cites W2735633909 @default.
• W3135712462 cites W2738239402 @default.
• W3135712462 cites W2764028271 @default.
• W3135712462 cites W2770448369 @default.
• W3135712462 cites W2793503277 @default.
• W3135712462 cites W2794683780 @default.
• W3135712462 cites W2883552344 @default.
• W3135712462 cites W2907154866 @default.
• W3135712462 cites W2908838385 @default.
• W3135712462 cites W2924425191 @default.
• W3135712462 cites W2934987713 @default.
• W3135712462 cites W2937998943 @default.
• W3135712462 cites W2945194536 @default.
• W3135712462 cites W2951928817 @default.
• W3135712462 cites W2964585156 @default.
• W3135712462 cites W2972427828 @default.
• W3135712462 cites W2998292126 @default.
• W3135712462 cites W3008297302 @default.
• W3135712462 cites W3112827629 @default.
• W3135712462 cites W3121914114 @default.
• W3135712462 cites W4239546129 @default.
• W3135712462 doi "https://doi.org/10.1186/s12951-021-00885-6" @default.
• W3135712462 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8120847" @default.
• W3135712462 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33985511" @default.
• W3135712462 hasPublicationYear "2021" @default.
• W3135712462 type Work @default.
• W3135712462 sameAs 3135712462 @default.
• W3135712462 citedByCount "15" @default.
• W3135712462 countsByYear W31357124622021 @default.
• W3135712462 countsByYear W31357124622022 @default.
• W3135712462 countsByYear W31357124622023 @default.
• W3135712462 crossrefType "journal-article" @default.
• W3135712462 hasAuthorship W3135712462A5016354966 @default.
• W3135712462 hasAuthorship W3135712462A5018972190 @default.
• W3135712462 hasAuthorship W3135712462A5032473290 @default.
• W3135712462 hasAuthorship W3135712462A5038714250 @default.
• W3135712462 hasAuthorship W3135712462A5045541975 @default.
• W3135712462 hasAuthorship W3135712462A5056451408 @default.
• W3135712462 hasAuthorship W3135712462A5063870450 @default.
• W3135712462 hasAuthorship W3135712462A5064415871 @default.
• W3135712462 hasAuthorship W3135712462A5077420983 @default.
• W3135712462 hasAuthorship W3135712462A5084846045 @default.
• W3135712462 hasBestOaLocation W31357124621 @default.
• W3135712462 hasConcept C111337013 @default.
• W3135712462 hasConcept C121332964 @default.
• W3135712462 hasConcept C12554922 @default.
• W3135712462 hasConcept C126322002 @default.
• W3135712462 hasConcept C143425029 @default.
• W3135712462 hasConcept C15083742 @default.
• W3135712462 hasConcept C150903083 @default.
• W3135712462 hasConcept C155672457 @default.
• W3135712462 hasConcept C171250308 @default.
• W3135712462 hasConcept C18231593 @default.
• W3135712462 hasConcept C185544564 @default.
• W3135712462 hasConcept C185592680 @default.
• W3135712462 hasConcept C192562407 @default.
• W3135712462 hasConcept C207001950 @default.
• W3135712462 hasConcept C2776107976 @default.

• next